Investment Considerations
- NLS Pharmaceutics is advancing a pipeline of novel therapies targeting CNS disorders, addressing significant unmet medical needs.
- The global CNS therapeutics market is projected to reach USD 267.62 billion by 2034, offering substantial growth opportunities.
- The company’s lead asset, Mazindol ER, is in clinical development for narcolepsy and ADHD, targeting large patient populations.
- An experienced leadership team with expertise in neurology, psychiatry, and pharmaceutical development guides the company’s strategic direction.
- NLS Pharmaceutics is committed to developing safer and more effective CNS therapies, aligning with the growing demand for improved mental and behavioral health treatments.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. Founded in 2015 by a team of researchers, drug developers, and commercial leaders, the company aims to address unmet medical needs in neurobehavioral and neurocognitive disorders.
The company’s mission is to safeguard life and longevity by empowering the brain through all stages of life. NLS Pharmaceutics is committed to bringing safe and effective drugs to market that measurably improve mental and behavioral health, thereby enhancing the quality of life for patients worldwide.
Recognizing the global prevalence of CNS disorders, NLS Pharmaceutics focuses on developing therapies that are safer, better-tolerated, and efficacious. The company is headquartered in Zurich, Switzerland.
Products
NLS Pharmaceutics is advancing a pipeline of therapeutic candidates targeting various CNS disorders:
- Mazindol Extended Release (ER): The company’s lead asset, Mazindol ER, is in clinical development for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, mechanisms that are believed to address the symptoms of these disorders.
- NLS-4: Another pipeline candidate, NLS-4, is under investigation for the treatment of sleep-related disorders.
- NLS-8: This candidate is being developed for the treatment of neurodegenerative diseases.
The company’s research and development efforts are focused on advancing these candidates through clinical trials to bring new treatment options to patients with CNS disorders.
Market Opportunity
The global central nervous system therapeutics market is experiencing significant growth, driven by the increasing prevalence of neurological disorders and advancements in drug development. The market size was estimated at USD 140.44 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.4% from 2025 to 2030.
Factors contributing to this growth include an aging population, increased awareness of mental health issues, and a strong pipeline of late-stage clinical candidates. NLS Pharmaceutics’ focus on developing novel therapies for CNS disorders positions the company to capitalize on this expanding market.
Leadership Team
Alex Zwyer, Chief Executive Officer and Co-Founder, leads NLS Pharmaceutics with a background in pharmaceutical development and business strategy. He has been instrumental in guiding the company’s vision and growth since its inception.
Dr. Eric Konofal, Chief Scientific Officer and Co-Founder, brings extensive experience in neurology and psychiatry. His research has significantly contributed to the understanding and treatment of CNS disorders.
Nicole Fernandez, Chief Medical Officer, oversees the clinical development programs at NLS Pharmaceutics. With a strong background in clinical research, she ensures the advancement of the company’s therapeutic candidates through rigorous clinical trials.